文献速递眼底病与葡萄膜炎

3型黄斑新生血管中基于积液的视力预后:FLIP-3研究

FLUID-BASED VISUAL PROGNOSTICATION IN TYPE 3 MACULAR NEOVASCULARIZATION-FLIP-3 STUDY.
PubMed 文献 · Retina · 2022-01-01

这项多中心回顾性队列研究纳入未治疗3型黄斑新生血管患眼,按积液部位分为仅视网膜内积液组(A组)与视网膜内积液合并视网膜下积液和/或视网膜色素上皮下积液组(B组)。A组基线及积液完全消退时最佳矫正视力均优于B组,B组黄斑中心凹萎缩比例更高且所需抗VEGF注射次数更多。

要点

  • 仅视网膜内积液者基线及积液消退时视力优于合并其他腔隙积液者
  • 合并视网膜下或RPE下积液者积液完全消退时黄斑中心凹萎缩比例更高
  • 合并其他腔隙积液者达到积液完全消退所需抗VEGF注射次数更多

核心结论

  • 在3型黄斑新生血管中,视网膜内积液可能与较好视力相关,此点不同于其他类型新生血管性年龄相关性黄斑变性。
  • 孤立性视网膜内积液可能所需注射次数更少,并可能与更少黄斑中心凹萎缩相关。

研究设计与样本

  • 多中心、回顾性队列研究,纳入未治疗的3型黄斑新生血管患眼,分析不同腔隙的积液情况。
  • A组为孤立性视网膜内积液;B组为视网膜内积液合并视网膜下积液和/或视网膜色素上皮下积液。

主要发现

  • A组31眼(55.3%),基线最佳矫正视力为20/50 Snellen等效(0.42±0.31 logMAR),积液完全消退时为20/50 Snellen等效(0.40±0.28 logMAR)。
  • B组基线最佳矫正视力为20/80 Snellen等效(0.64±0.35 logMAR)(P=0.0181),积液完全消退时为20/100 Snellen等效(0.70±0.40 logMAR)(P=0.0021)。
  • 积液完全消退时,B组黄斑中心凹萎缩为82.6%(19/23),A组为51.6%(16/31)。
  • B组达到积液完全消退所需抗VEGF注射次数为10.3±9.0次,A组为5.7±4.8次。

临床怎么用

  • 对3型黄斑新生血管可按积液腔隙分层评估视力预后与治疗负担。
  • 孤立性视网膜内积液者可能需较少抗VEGF注射,合并其他腔隙积液者需关注黄斑中心凹萎缩。

局限性

  • 原文为回顾性队列设计,未报告随机化、盲法及混杂因素调整等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze the effect of fluid on visual acuity in cases of Type 3 macular neovascularization. METHODS: This multicentric, retrospective cohort study included eyes with treatment-naïve Type 3 macular neovascularization. Analysis of fluid in different compartments was performed. Group A included eyes with isolated intraretinal fluid, whereas Group B included eyes with intraretinal fluid in conjunction with subretinal fluid and/or sub retinal pigment epithelial fluid. RESULTS: Eyes in Group A (31, 55.3%) had better best-corrected visual acuity of 20/50 snellen equivalent (0.42 ± 0.31 logarithm of the minimum angle of resolution) at baseline and 20/50 snellen equivalent (0.40 ± 0.28 logarithm of the minimum angle of resolution) at complete resolution compared with Group B with visual acuity of 20/80 snellen equivalent (0.64 ± 0.35 logarithm of the minimum angle of resolution) (P = 0.0181) at baseline and 20/100 snellen equivalent (0.70 ± 0.40 logarithm of the minimum angle of resolution) (P = 0.0021) at complete resolution. Subfoveal atrophy was more in Group B (82.6% 19/23) at complete resolution in comparison to Group A (16/31, 51.6%). Eyes in Group B needed more anti-vascular endothelial growth factor injections (10.3 ± 9.0) for complete resolution compared with Group A (5.7 ± 4.8). CONCLUSION: Intraretinal fluid may be associated with good visual acuity in Type 3 macular neovascularization in contrast to other forms of neovascular age related macular degeneration. Furthermore, intraretinal fluid in isolation may need fewer injections and could probably be associated with less subfoveal atrophy.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Sharma A, Cheung CMG, Arias-Barquet L, et al. FLUID-BASED VISUAL PROGNOSTICATION IN TYPE 3 MACULAR NEOVASCULARIZATION-FLIP-3 STUDY. Retina. 2022. PMID: 34255761. doi:10.1097/IAE.0000000000003261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。